Kenneth M. Algazy

1.4k total citations
15 papers, 723 citations indexed

About

Kenneth M. Algazy is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Otorhinolaryngology. According to data from OpenAlex, Kenneth M. Algazy has authored 15 papers receiving a total of 723 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pulmonary and Respiratory Medicine, 8 papers in Oncology and 5 papers in Otorhinolaryngology. Recurrent topics in Kenneth M. Algazy's work include Lung Cancer Treatments and Mutations (8 papers), Head and Neck Cancer Studies (5 papers) and Lung Cancer Research Studies (4 papers). Kenneth M. Algazy is often cited by papers focused on Lung Cancer Treatments and Mutations (8 papers), Head and Neck Cancer Studies (5 papers) and Lung Cancer Research Studies (4 papers). Kenneth M. Algazy collaborates with scholars based in United States, Canada and Germany. Kenneth M. Algazy's co-authors include Mitchell Machtay, Theodore J. Robnett, Michael G. McKenna, W. Gillies McKenna, James Stevenson, Stephen M. Hahn, Andrei Z. Budzynski, Renate L. Soulen, Suhas G. Parulekar and Vichai Atichartakarn and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Kenneth M. Algazy

15 papers receiving 689 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kenneth M. Algazy United States 8 432 195 193 174 150 15 723
Ángel Olazábal Spain 8 895 2.1× 445 2.3× 137 0.7× 89 0.5× 178 1.2× 11 1.1k
L. Falchero France 18 1.0k 2.4× 673 3.5× 333 1.7× 52 0.3× 127 0.8× 71 1.4k
Caroline Brammer United Kingdom 8 109 0.3× 220 1.1× 40 0.2× 100 0.6× 142 0.9× 14 546
Alastair N.J. Graham United Kingdom 15 437 1.0× 192 1.0× 116 0.6× 53 0.3× 330 2.2× 44 828
Krzysztof Urbański Poland 13 85 0.2× 131 0.7× 102 0.5× 144 0.8× 118 0.8× 56 576
Candice Johnstone United States 11 334 0.8× 295 1.5× 121 0.6× 26 0.1× 160 1.1× 44 660
W. Appel United Kingdom 7 274 0.6× 395 2.0× 37 0.2× 106 0.6× 61 0.4× 13 620
Daniel Reed United States 12 237 0.5× 67 0.3× 103 0.5× 51 0.3× 66 0.4× 45 551
Shintaro Shirai Japan 15 183 0.4× 70 0.4× 54 0.3× 72 0.4× 215 1.4× 41 566
Lionel Duck Belgium 11 279 0.6× 490 2.5× 73 0.4× 21 0.1× 313 2.1× 33 837

Countries citing papers authored by Kenneth M. Algazy

Since Specialization
Citations

This map shows the geographic impact of Kenneth M. Algazy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kenneth M. Algazy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kenneth M. Algazy more than expected).

Fields of papers citing papers by Kenneth M. Algazy

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kenneth M. Algazy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kenneth M. Algazy. The network helps show where Kenneth M. Algazy may publish in the future.

Co-authorship network of co-authors of Kenneth M. Algazy

This figure shows the co-authorship network connecting the top 25 collaborators of Kenneth M. Algazy. A scholar is included among the top collaborators of Kenneth M. Algazy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kenneth M. Algazy. Kenneth M. Algazy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Weiss, Jared, D. Neil Hayes, Kenneth M. Algazy, et al.. (2013). Combination lapatinib and capecitabine in advanced, incurable squamous cell carcinoma of the head and neck (SCCHN).. Journal of Clinical Oncology. 31(15_suppl). 6094–6094. 3 indexed citations
2.
Campling, Barbara G., Bradley N. Collins, Kenneth M. Algazy, Robert A. Schnoll, & Miu Lam. (2011). Spontaneous Smoking Cessation Before Lung Cancer Diagnosis. Journal of Thoracic Oncology. 6(3). 517–524. 7 indexed citations
3.
Algazy, Kenneth M., Lynn M. Schuchter, Angela DeMichele, et al.. (2011). Abstract 4500: Combined mTOR inhibition and autophagy inhibition: Phase I trial of temsirolimus and hydroxchloroquine in patients with advanced solid tumors. Cancer Research. 71(8_Supplement). 4500–4500. 2 indexed citations
4.
Fury, Matthew G., Eric J. Sherman, Kenneth M. Algazy, et al.. (2011). A randomized phase II study of cetuximab (C) every 2 weeks at either 500 or 750 mg/m2 for patients (Pts) with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC).. Journal of Clinical Oncology. 29(15_suppl). 5563–5563. 3 indexed citations
5.
Rosenthal, David I., Clifton D. Fuller, Mitchell Machtay, et al.. (2006). Phase I Study of Paclitaxel Given by Seven-Week Continuous Infusion Concurrent with Radiation Therapy for Locally Advanced Non???Small Cell Lung Cancer. Journal of Thoracic Oncology. 1(1). 38–45. 3 indexed citations
6.
Campling, Barbara G., Wei‐Ting Hwang, Jiameng Zhang, et al.. (2005). A population‐based study of lung carcinoma in Pennsylvania. Cancer. 104(4). 833–840. 31 indexed citations
7.
Machtay, Mitchell, Jason H. Lee, James Stevenson, et al.. (2004). Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non–small cell lung carcinoma: long-term results and associations with pathologic response. Journal of Thoracic and Cardiovascular Surgery. 127(1). 108–113. 45 indexed citations
8.
Flaherty, Keith T., et al.. (2004). A phase I, dose escalation trial of ZD0473, a novel platinum analogue, in combination with gemcitabine. Cancer Chemotherapy and Pharmacology. 53(5). 404–408. 12 indexed citations
9.
Flaherty, Keith T., James Stevenson, Maryann Gallagher, et al.. (2003). Dose escalation study of tezacitabine in combination with cisplatin in patients with advanced cancer. Cancer. 97(8). 1985–1990. 5 indexed citations
10.
Campling, Barbara G., et al.. (2002). Clinical and Molecular Features of Small cell Lung Cancer. Cancer Biology & Therapy. 1(2). 105–112. 2 indexed citations
11.
Robnett, Theodore J., Mitchell Machtay, James Stevenson, Kenneth M. Algazy, & Stephen M. Hahn. (2001). Factors Affecting the Risk of Brain Metastases After Definitive Chemoradiation for Locally Advanced Non–Small-Cell Lung Carcinoma. Journal of Clinical Oncology. 19(5). 1344–1349. 137 indexed citations
12.
Robnett, Theodore J., et al.. (2000). Factors predicting severe radiation pneumonitis in patients receiving definitive chemoradiation for lung cancer. International Journal of Radiation Oncology*Biology*Physics. 48(1). 89–94. 234 indexed citations
13.
Machtay, Mitchell, David I. Rosenthal, Kenneth M. Algazy, et al.. (2000). Pilot Study of Organ Preservation Multimodality Therapy for Locally Advanced Resectable Oropharyngeal Carcinoma. American Journal of Clinical Oncology. 23(5). 509–515. 13 indexed citations
14.
Robnett, Theodore J., Mitchell Machtay, Eugenio Vinés, et al.. (1999). 2213 Factors predicting severe radiation pneumonitis in patients receiving definitive chemoradiation for lung cancer. International Journal of Radiation Oncology*Biology*Physics. 45(3). 388–388. 6 indexed citations
15.
Marder, Victor J., Renate L. Soulen, Vichai Atichartakarn, et al.. (1977). Quantitative venographic assessment of deep vein thrombosis in the evaluation of streptokinase and heparin therapy.. PubMed. 89(5). 1018–29. 220 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ángel Olazábal Breakdown of academic impact, for papers by L. Falchero Breakdown of academic impact, for papers by Caroline Brammer Breakdown of academic impact, for papers by Alastair N.J. Graham Breakdown of academic impact, for papers by Krzysztof Urbański Breakdown of academic impact, for papers by Candice Johnstone Breakdown of academic impact, for papers by W. Appel Breakdown of academic impact, for papers by Daniel Reed Breakdown of academic impact, for papers by Shintaro Shirai Breakdown of academic impact, for papers by Lionel Duck
Rankless by CCL
2026